Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Cartesian Therapeutics ( (RNAC) ).
On October 29, 2025, Carrie S. Cox resigned from her roles at Cartesian Therapeutics to focus on her new appointment as Executive Chair of another company. Her departure led to the appointment of Carsten Brunn, Ph.D., as Chairman of the Board, with Patrick Zenner as Lead Independent Director and Kemal Malik as Chairman of the Compensation Committee. The company also amended its bylaws to reflect these changes. These leadership changes are expected to support Cartesian’s strategic focus on advancing its cell therapy pipeline, particularly Descartes-08, towards regulatory submission and potential commercial launch.
The most recent analyst rating on (RNAC) stock is a Sell with a $9.50 price target. To see the full list of analyst forecasts on Cartesian Therapeutics stock, see the RNAC Stock Forecast page.
Spark’s Take on RNAC Stock
According to Spark, TipRanks’ AI Analyst, RNAC is a Underperform.
The overall stock score is primarily driven by significant financial challenges, including declining revenues, negative equity, and weak cash flows. Technical analysis indicates a bearish trend, with the stock trading below key moving averages and approaching oversold conditions. The negative P/E ratio and lack of dividend yield further weigh on the valuation, resulting in a low overall score.
To see Spark’s full report on RNAC stock, click here.
More about Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases. Its lead asset, Descartes-08, is in Phase 3 clinical development for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus, with plans for a Phase 2 basket trial in additional autoimmune indications. The company’s pipeline also includes Descartes-15, a next-generation CAR-T therapy for multiple myeloma.
Average Trading Volume: 87,101
Technical Sentiment Signal: Sell
Current Market Cap: $213.2M
Find detailed analytics on RNAC stock on TipRanks’ Stock Analysis page.